Currently approved treatments for schizophrenia only minimally affect the cognitive features of the illness that are the most closely related to disability. Hence, there is now considerable effort to repurpose drugs for schizophrenia, and to seek agents that can improve cognition by targeting receptor systems other than the dopaminergic system. The results of these studies have been mixed thus far; however, this continues to be a high-priority area of schizophrenia research and an important unmet need.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: